Last updated: February 23, 2026
What is the Drug Corresponding to NDC 00378-0437?
NDC 00378-0437 corresponds to Xolair (omalizumab). Xolair is a prescribed monoclonal antibody used primarily for allergic asthma, chronic spontaneous urticaria, and nasal polyps. Manufactured by Novartis, it was approved by the FDA in 2003.
Market Overview
Therapeutic Area and Indication Penetration
- Asthma: Prevalence in the U.S. is approximately 8% of adults and 7% of children. Xolair targets allergic asthma, accounting for roughly 20% of adult asthma cases.
- Chronic Spontaneous Urticaria (CSU): Affecting about 1% of the population, Xolair is a second-line therapy after antihistamines.
- Nasal Polyps: Growing indication, especially after FDA approval in 2019.
Market Size and Forecast
| Measure |
2022 |
2023 (Projection) |
2028 (Projection) |
| U.S. Asthma Patients |
25 million |
26 million |
27 million |
| CSU Patients |
3 million |
3.2 million |
3.5 million |
| Nasal Polyps Prevalence |
5 million |
5.2 million |
5.7 million |
| Total Potential Patients |
33 million |
34.4 million |
36.2 million |
Market penetration estimates suggest:
- Asthma: 15% currently treated with biologics (including Xolair).
- CSU: 10% of eligible patients treated.
- Nasal Polyps: 25% uptake post-approval.
Key Competitive Landscape
- Biologics Market Segments: Dupilumab (Dupixent), mepolizumab (Nucala), reslizumab (Cinquair), benralizumab (Fasenra).
- Market Share (2022):
- Xolair: 45%
- Dupixent: 30%
- Mepolizumab: 15%
- Others: 10%
Pricing and Reimbursement
- Average Wholesale Price (AWP): Approx. $7,000 per 150 mg dose.
- Average Cost per Patient per Year: $30,000 – $40,000, depending on dosing frequency.
- Reimbursement Dynamics: Payers increasingly favor biosimilar or alternative biologics; however, Xolair's established efficacy sustains premium pricing.
Price Projections
Current Pricing
- List Price: Around $7,000 per dose, with typical doses ranging from 150 mg to 300 mg monthly.
- Annual Cost: $30,000–$40,000 per patient.
Future Pricing Trends (2023–2028)
| Year |
Estimated List Price (per dose) |
Approximate Annual Cost per Patient |
Drivers |
| 2023 |
$7,000 |
$30,000 |
Stable, no significant price cuts |
| 2024 |
$6,800 |
$29,000 |
Competitive pressure, biosimilars |
| 2025 |
$6,750 |
$28,000 |
Patent expiry influence |
| 2026 |
$6,700 |
$27,000 |
Biosimilar market penetration |
| 2027 |
$6,500 |
$25,000 |
Increased biosimilar uptake |
| 2028 |
$6,500 |
$25,000 |
Patent cliff, market saturation |
Impact Factors
- Biosimilar Competition: Expected to debut by 2024-2026, potentially reducing prices by 20-30%.
- Market Demand Growth: Moderate, driven by expanding indications and increasing diagnosis rates.
- Reimbursement Policies: Shift toward value-based agreements may pressure prices.
Strategic Considerations for Stakeholders
- Pharmaceutical Companies: Focus on biosimilar development and licensing deals.
- Payers: Enforce utilization management, prioritize biosimilars.
- Clinicians: Emphasize personalized medicine approaches and alternative therapies.
Key Takeaways
- The global Xolair market is approximately $3 billion annually, with U.S. comprising about 70%.
- Price per dose remains around $7,000, but competition and biosimilar entry may push prices downward.
- Market growth is supported by expanding indications but faces pressure from emerging biologics.
FAQs
1. Is Xolair's patent expiration imminent?
Xolair's primary patents are expected to expire in the U.S. around 2027-2028, opening the market for biosimilars.
2. How do biosimilars affect Xolair’s pricing?
Biosimilars are projected to reduce prices by 20-30% once they enter the market, impacting Xolair’s revenue.
3. What are the key drivers for Xolair market growth?
Increasing diagnosis rates, expanding indications, and clinician familiarity drive growth. However, biosimilar competition constrains prices.
4. How does Xolair compare economically to other biologics?
Xolair is priced similarly to dupilumab but varies based on dosing and indication. Biosimilars are expected to be 20-30% cheaper.
5. What are the main risks for Xolair revenue?
Patent expiry, biosimilar competition, payer pressure, and changes in treatment guidelines pose revenue risks.
Sources
- FDA. (2022). Xolair (omalizumab) prescribing information. https://www.accessdata.fda.gov
- IQVIA. (2023). Biologics market review and forecast.
- Reuters. (2022). Biosimilar bios patent cliff analysis.
- Centers for Disease Control and Prevention. (2022). Asthma prevalence data.
- MarketWatch. (2023). Biologics pricing trends and forecasts.
